News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Paolo Tarantino: Our study on the prognosis of small TNBCs is out in NPJ Journals
Photo of Paolo Tarantino taken from Twitter
Apr 10, 2024, 05:00

Paolo Tarantino: Our study on the prognosis of small TNBCs is out in NPJ Journals

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Our study on the prognosis of small TNBCs is out in NPJ Journals Breast. Among 8601 pts with stage I TNBC in SEER, we found excellent 5-year outcomes, with a significant BCSS benefit for chemo in pT1c. Benefit less clear in tumors ≤1cm: biomarkers needed! ”

Paolo Tarantino: Our study on the prognosis of small TNBCs is out in NPJ Journals

Read further.
Source: Paolo Tarantino/X

cancer Dana-Farber Cancer Institute npj Journals OncoDaily Oncology Paolo Tarantino tumor biomarkers
Special Coverage
Science
Dec 31, 2024, 03:34
Cristian Ochoa Arnedo: Empowerment among breast cancer survivors using an online peer support community
Blog
Dec 30, 2024, 19:52
CelloType: A New Machine Learning Tool for Analyzing Cancer Cells and Tissues
Blog
Dec 30, 2024, 19:26
“QI Scholar Nursing Presentations Part 2” from the SIOP Nursing Network
Science
Dec 30, 2024, 13:52
Nico Gagelmann: Selected clinical studies 2024 in hematology
Insight
Dec 30, 2024, 13:43
Roupen Odabashian: When it comes to real-life cases, physicians still outperform AI
Blog
Dec 30, 2024, 13:42
Shaban Juma: The key to being one step ahead in the fight against cancer
Positive
Dec 30, 2024, 13:42
Improving the lives of children with cancer everywhere - St. Jude Children's Research Hospital
Blog
Dec 30, 2024, 13:37
Matthew Pech: The failure of ex vivo gene therapy for sickle cell and the role of the TPP in the drug development process
Insight
Dec 30, 2024, 13:35
James Crowley: Elevated expression of CCR7 is generally indicative of poor prognosis in cancers
Insight
Dec 30, 2024, 13:30
Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
Blog
Dec 30, 2024, 13:25
Sanjay Popat: Wouldn’t it be great if FDA Oncology approvals were mutually approvable by MHRA?
Insight
Dec 30, 2024, 13:23
Satya Prakash Yadav: 2024 blockbuster Menin inhibitor for infant ALL